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Abstract
CD38 is a transmembrane glycoprotein expressed on the surface of different cell 
lines with several functions (receptor, adhesion molecule, ectoenzyme). Based on 
its high expression in multiple myeloma cells, CD38 is one of the main molecules 
used in the target therapy age. Daratumumab is the first fully human monoclonal 
antibody tested in clinical trials, showing efficacy in relapsed/refractory multiple 
myeloma patients, especially in combination with immunomodulants and/or pro-
teasome inhibitors. The synergic effect concerns multiple myeloma cells as well as 
the microenvironment (NK cells, macrophage, regulatory B/T cells and CD8+ effec-
tor cells). Therefore, the anti-multiple myeloma activity of Daratumumab greatly 
depends on the immune system: this is the reason why several ongoing clinical trial 
are testing its efficacy in the naïve patients, with a more effective immune system.
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1. Introduction: mechanism of action
Daratumumab is the first fully IgG1K-human monoclonal antibody targeting 
CD38.CD38, also known as cyclic ADP ribose hydrolase, is a transmembrane glyco-
protein expressed on the surface of hematopoietic and non-hematopoietic cell lines.
This protein plays different functions, both on the external and on the inner 
surface of cells. As a receptor, it takes part into the inflammatory response, stimu-
lating the production of a great variety of cytokines through the interaction with 
CD31, on the surface of T cells. As enzyme, it is involved in the metabolism of 
nicotinamide adenine dinucleotide (NAD+), leading to the synthesis of cyclic ADP 
ribose (cADPR) which regulates cellular calcium trafficking [1].
In the context of bone niche, CD38 expression is very high on the surface of 
plasma cells. Pioneering studies have shown that this glycoprotein plays a key-role 
in the oncogenesis of multiple myeloma: increased intracellular levels of NAD+ 
seem to be associated with a less susceptibility to apoptosis [2] and the synthesis of 
cADPR favours the escape of tumour cells from the immune system [3]. In vitro, 
CD38 seems also to be associated with the formation of nanotubes that transfer 
mitochondria from the stromal cells to myeloma cells, boosting myeloma cell 
proliferation and survival [4].
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Daratumumab binds CD38, killing tumour cells via Fc-dependent immune  effector 
mechanisms including complement-dependent cytotoxicity (CDC), antibody- 
dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular 
phagocytosis (ADCP) [5]. The complement activation seems to be the most effective 
mechanism used by Daratumumab [6]: the Fc tail of the drug binds the activating factor 
C1q leading both to ultimate activation of membrane attack complex and to deposition 
of C3b on the surface of multiple myeloma plasma cells. The activation of membrane 
attack complex causes osmotic lysis of cells while the deposition of complement factors 
attracts phagocytic cells. The recruitment of immune effector cells is also boosted by the 
release of circulating factors such as C3 and C5a (Figure 1).
The anti-tumour activity of Daratumumab does not depend only on the direct 
action on plasma cells but also on the interaction with other lymphoid and myeloid 
cells with a weak expression of CD38: NK cells, B and T regulatory cells and CD8+ 
effector cells. Krejcik et al. have demonstrated that bone marrow and peripheral 
blood from patients on treatment with Daratumumab present low levels of regula-
tory cells and high levels of NK and CD8+ effector cells. This monoclonal antibody 
may interfere with the immunosuppressive microenvironment in the multiple 
myeloma bone niche, in favour of major susceptibility for the plasma cells to the NK 
and CD8+ cells toxicity [7].
2. Pharmacokinetics
Daratumumab is usually administered at the dosage of 16 mg/kg weekly for 
8 weeks then every 2 weeks for 16 weeks and every 4 weeks thereafter until progres-
sion of disease. The administration on a mg/kg basis is due to the observation that 
distribution and clearance of daratumumab depends on bodyweight. It seems to be 
not influenced by age, gender, race, mild renal and liver impairment. To our knowl-
edge, the extra-liver metabolism of daratumumab is the reason for the absence of 
interactions with other drugs.
The efficacy and safety of this schedule have been demonstrated by two studies 
involving patients with relapsed/refractory multiple myeloma (RRMM) treated 
with the anti-CD38 monoclonal antibody as single agent: GEN501 and SIRIUS.
GEN501 was a phase I/II, open-label, multicenter study. In the dose-escalation 
part, sequential cohorts of patients received intravenous doses of daratumumab 
ranging from 0.005 to 24 mg/kg, administered over 6–8 h. In the dose-expansion 
Figure 1. 
Mechanism of action of daratumumab. Daratumumab binds CD38, killing myeloma cells via Fc-dependent 
immune effector mechanisms: CDC, ADCC and ADCP. Daratumumab also inhibits enzymatic activity of 
CD38, downregulating intracellular Ca2+ trafficking.
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study, in three of the enrolled cohorts, daratumumab was administered based on 
the findings from the previous part at 8 mg/kg weekly for 8 weeks, every 2 weeks 
for 16 weeks, and every 4 weeks until disease progression [8].
SIRIUS was a phase II study with two parts. In the first part, the patients were 
randomized to receive daratumumab 8 mg/kg every 4 weeks or 16 mg/kg weekly 
for 8 weeks, then every 2 weeks for 16 weeks and every 4 weeks thereafter. In the 
second part, all patients received daratumumab 16 mg/kg, according to the findings 
from the first part [9].
Intravenous administration of Daratumumab is associated with several side 
effects, included infusion-related reactions (see below). Therefore, this formula-
tion requires a very slow infusion rate which may represent a disadvantage for the 
patient. Sever trials are evaluating the subcutaneous administration as an alterna-
tive. In the phase 1b PAVO study, the subcutaneous formulation of the monoclonal 
antibody was administered in patients with RRMM in combination with the 
recombinant human hyaluronidase PH20 enzyme (rHuPH20) to depolymerize 
hyaluronan in the subcutaneous space and increase the absorption rate [10]. This 
formulation at the dosage of 1800 mg was well tolerated and allowed to obtain simi-
lar concentrations and responses to the intravenous administration. Non-inferiority 
of subcutaneous daratumumab to intravenous formulation has been confirmed by 
preliminary results of the ongoing phase III trial COLUMBA [11]: enrolled patients 
with RRMM are randomized to receive either intravenous daratumumab 16 mg/kg 
or subcutaneous daratumumab 1800 mg. According to these studies, the approval 
of this formulation by the regulatory bodies is on the agenda.
3. Daratumumab in relapsed/refractory multiple myeloma
Approval of daratumumab by regulatory bodies was made possible thanks to 
clinical trials evaluating its use in RRMM. Patients with RRMM still represent the 
patients best benefitting from this monoclonal antibody, both as single agent and in 
combination with other agents (Table 1a).
3.1 Daratumumab in relapsed/refractory multiple myeloma as single agent
GEN501 and SIRIUS are the two main trials who led to approval of monotherapy 
with daratumumab. Both studies enrolled patients with RRMM: patients in GEN501 
had relapsed after or were refractory to ≥2 prior lines of therapy, including inhibi-
tors of proteasome (PIs), immunomodulatory drugs (IMiDs), chemotherapy and 
autologous stem cell transplantation (ASCT); patients in SIRIUS had relapsed 
after ≥3 lines of therapy, including a PI and a IMiDs or were double refractory to 
the most recently received PI and IMiDs. The primary endpoint of GEN501 was 
evaluation of safety while SIRIUS was designed to first evaluate overall response 
rate (ORR). Data regarding 148 patients from pooled analysis of the two trials 
confirmed how daratumumab, at the dosage of 16 mg/kg, is effective and safe in a 
population of heavily pretreated patients [12]. With a median number of 12 infu-
sions, the ORR was 31.1%. At the time of the analysis, after a median follow-up of 
20.7 months, the progression free survival (PFS) was 4 months, with a 12-month 
PFS rate of 22%. Stratifying the patients by the response according to International 
Myeloma Working Group, the PFS and the overall survival (OS) went out to be 
15 months and not reached respectively for responders, 3 months and 18.5 months 
for patients with a stable disease or minimal response, 0.9 months and 3.7 months 
for non-responders. The median duration of response was 7.6 months and it deep-
ened and improved in patients continuing daratumumab.
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3.1.1  Daratumumab in relapsed/refractory multiple myeloma in combination 
therapies: with IMiDs
Efficacy of daratumumab seems to be strengthened by other drugs used for 
multiple myeloma, given the synergic action on the immune system. As said 
before, the anti-CD38 may stimulate NK and T-cells, restoring “tumor suppressive 
immunological surveillance”. Also IMiDs could increase the amount of regulatory 
cells in the bone niche, through inhibition of some transcriptional factors (Ikaros 
and Aialos) and the subsequent production of interleukin 2 [13]. Furthermore, 
some studies show that the main target of daratumumab is upregulated by action 
of IMiDs [14]. NCT01615029 was the first trial exploring the applicability of these 
laboratory observations, investigating efficacy of daratumumab in combination 
with lenalidomide and dexamethasone (Rd) [15]. It was a phase 1/2 study addressed 
to patients with relapsed multiple myeloma: phase 1 was a dose-escalation study in 
which the dose of 16 mg/kg for daratumumab was again determined; phase 2 was 
a dose-expansion study using the recommended dose of the first part. The three 
drugs were administered in cycle of 28 days: daratumumab was given according to 
the standard schedule, lenalidomide at 25 mg/day from days 1 to 21 of each cycle 
and dexamethasone at 40 mg/week. This combination revealed to be safe and very 
effective: the 18-months PFS rate was 72% and ORR was 81%, in this case too with 
an improvement of responses in time. To evaluate the advantage of adding daratu-
mumab to a regimen with lenalidomide and dexamethasone, from 2014 to 2015, a 
phase III, randomized trial was carried out across Europe, Northern America and 
Asia [16]. The POLLUX trial enrolled 569 patients with multiple myeloma who had 
Trial Phase Therapy Primary outcome
(a) RRMM
GEN501 1/2 IV daratumumab single agent evaluation of safety
SIRIUS 2 IV daratumumab single agent ORR
PAVO 1B SC daratumumab Maximum ctrough
N° of patients with AEs




NCT01615029 1 / 2 DARA-Rd ORR
CASTOR 3 DARA-Vd vs Vd PFS
POLLUX 3 DARA-Rd vs Rd PFS
(b) NDMM
ALCYONE 3 DARA-VMP vs VMP PFS
MAIA 3 DARA-Rd vs DARA-Rd PFS
CASSIOPEIA 3 DARA-VTd vs VTd sCR after consolidation
PFS
GRIFFIN 2 DARA-RVd vs RVd sCR after consolidation
PERSEUS 3 DARA-RVd vs RVd PFS
RRMM: Relapsed/Refractory Multiple Myeloma, IV: intravenous, SC: subcutaneous, Rd.: lenalidomide-
dexamethasone, Vd: bortezomib-dexamethasone, ORR: Overall Response Rate, Maximum CTrough: Maximum 
Concentration Trough, AEs: Advese Events, PFS: Progression Free Survival, NDMM: Newly Diagnosed Multiple 
Myeloma, VMP: bortezomib-melphalan-dexamethasone, VTd: bortezomib-thalidomide-dexamethasone, RVd: 
lenalidomide-botrezomib-dexamethasone, sCR: stringent Complete Response.
Table 1.  
Overview of main trials using Daratumumab in (a) RRMM, (b) NDMM.
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received one or more previous lines of therapy: 286 were assigned to the daratu-
mumab group (daratumumab plus lenalidomide and dexamethasone) and 283 to 
the control group (lenalidomide and dexamethasone). Also in this trial, each cycle 
was of 28 days, with daratumumab administered according to the usual schedule, 
lenalidomide at 25 mg/day from days 1 to 21 of each cycle and dexamethasone at a 
dose of 40 mg weekly. At 12 months, the PFS rate was 83.2% in the daratumumab 
group vs 60.1% in the control group. In a sub analysis, this extension of PFS in the 
experimental group went out to be independent from the number of previous lines 
of therapy and from the previous exposure to lenalidomide, even if the paucity 
of refractory patients to IMiDs enrolled in this trial may represent a bias. After a 
follow-up of 13.5 months, progression disease or death occurred in 53 patients in 
the daratumumab group vs 116 patients in the control arm, with a hazard ratio of 
0.37 in favour of the first group. Also in this case, an improvement of deepness of 
molecular response was observed with continuation of therapy with the mono-
clonal antibody and it translated in a longer survival. Indeed, 22.4% of patients 
in the experimental group had results below the threshold for minimal residual 
disease (MRD), compared to 4.6% in the control group. Neutropenia, diarrhea and 
infusional reactions were the main adverse events reported in the experimental arm 
with a higher incidence than in the control group but, in spite of that, the rate of 
grade 3 and grade 4 infections was not so different. In conclusion, POLLUX trial 
confirmed the efficacy and safety of adding daratumumab to a regimen with IMiDs 
and high-dose steroid. Furthermore, the excellent results below the threshold for 
minimal residual disease suggest that minimal residual disease negativity could 
represent a goal also for RRMM patients.
3.1.2  Daratumumab in relapsed/refractory multiple myeloma in combination 
therapies: with PIs
Some in-vitro studies have shown that not only IMiDs but also PIs interact with 
daratumumab in a synergic way, strengthening its effect. An assay performed by 
the Dutch group [14] evaluated the rate of lysis in samples of bone marrow mono-
nuclear cells from 16 multiple myeloma patients incubated with medium contain-
ing either daratumumab, lenalidomide and bortezomib or just one drug. The rate 
of lysis went out to be higher in the samples with the addition of daratumumab, 
showing that not only lenalidomide but also bortezomib enhance the effect of this 
monoclonal antibody by sensitizing the cells to the antibody-mediated lysis. The 
“lysis effect” was even better in cells from patients who previously showed refracto-
riness to IMiDs or IPs, suggesting that immunomodulatory effects of daratumumab 
may restore host susceptibility to anti-myeloma agents. Based on a phase 1b trial in 
which daratumumab showed encouraging results in combination with PIs-based 
regimens in naive patients [17], a phase 3 trial randomized patients with relapsed 
and/or refractory multiple myeloma to a treatment with only bortezomib and dexa-
methasone or with the addition of daratumumab [18]. Of 498 patients, 251 were 
assigned to the daratumumab group and 247 to the control group. Each cycle had a 
duration of 21 days. Daratumumab was administered at the usual dosage of 16 mg/
kg once per week during cycles 1 to 3, once every 3 weeks during cycles 4 to 8 and 
once every 4 weeks thereafter until toxicity or progression disease. Dexamethasone 
was given for a total dose of 160 mg per cycle and bortezomib was administered in 
the subcutaneous formulation at the dosage of 1.3 mg per square meter on days 1, 4, 
8 and 11 of cycles 1 to 8. The 12-month rate of PFS was 60.7% in the experimental 
group and 26.9% in the control group. After a follow up of 7.4 months, progression 
disease or death occurred in 67 patients in the daratumumab group vs 122 in the 
control group. Given the results of the interim analysis, the trial was unblended 
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earlier and patients in the control group with a progression disease were offered 
daratumumab monotherapy. This may represent a bias in the interpretation of all 
the long-term results. Nevertheless, this trial showed how daratumumab could give 
an advantage also in combination with PIs-based regimens. The recorded responses 
are deep and durable. The main adverse events reported in the daratumumab group 
were thrombocytopenia and infusion-related reactions but none of them led to a 
treatment discontinuation higher than in the control group.
3.1.3  Daratumumab in relapsed/refractory multiple myeloma in combination 
therapies: the experience from the Multiple Myeloma GIMEMA Lazio Group
Fazio et al. performed a multicentre retrospective analysis of patients with 
relapsed/refractory multiple myeloma treated with IMiDs or IPs-based regimens 
containing daratumumab in the hospitals of the GIMEMA (Gruppo Italiano 
Malattie Ematologiche dell’Adulto) network in the Italian region of Lazio [19]. Of 
188 patients, sixty-five performed at least one cycle of therapy and were evaluable 
for hematologic response. The ORR was 81.97%; with four patients (6.56%) achiev-
ing a stringent complete response (sCR), 20 (32.79%) patients a complete response 
(CR), 5 (8.2%) patients a non-complete response (NCR), 13 (21.31%) patients a 
very good partial response (VGPR) and 8 (13.11%) patients a partial response (PR). 
After a median follow-up of 8.8 (range 0.23–22.3) months, 50 (42.37%) patients 
were alive maintaining response, eight (13.11%) patients presented a progression 
disease and one (1.64%) patients died. The overall survival and progression-free 
survival were 86.3% (95% CI, 79.2–94) and 70.8% (95% CI, 61.2–82), respectively. 
The most common grade 3 or 4 hematologic treatment-emergent adverse events 
(TAEs) included neutropenia, anemia and thrombocytopenia. The most common 
non-hematologic TAEs, of any grade, were infections, peripheral sensory neuropa-
thy (7.6%) and fatigue (7.6%). Among the cases of infection, 17 (26%) patients 
presented pneumonia, eight (12%) patients FUO and five (7.7%) patients viral reac-
tivation. Our preliminary results confirm data from POLLUX and CASTOR trial, 
suggesting that treatment with daratumumab in combination with lenalidomide or 
bortezomib plus dexamethasone is a highly effective and well-tolerated regimen to 
be considered for multiple myeloma patients after first relapse.
3.1.4  Daratumumab in relapsed/refractory multiple myeloma in combination 
therapies: with other novel agents
In the setting of heavily pretreated myeloma patients, daratumumab has shown 
good results also in association with novel drugs belonging to the last generations 
of IMiDs and IPs. Both combination of daratumumab with pomalidomide and 
dexamethasone and with carfilzomib and dexamethasone allowed to obtain deep 
and durable responses with a tolerable toxicity profile [20, 21]. Therefore, it seems 
reasonable to use daratumumab in combination with triplets or quadruplets in 
RRMM to obtain the best response.
3.2  Daratumumab in relapsed/refractory multiple myeloma in combination 
therapy: after or before allogenic hematopoietic cell-transplantation for 
young patients?
Despite improvements in the MM outcome and in the depth and response dura-
tion following subsequent lines of therapy, MM remains an incurable disease. It is 
reasonable to consider allogenic (allo) hematopoietic cell transplantation (HCT) 
as a treatment strategy for young patients with high-risk disease and an available 
7
The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab
DOI: http://dx.doi.org/10.5772/intechopen.95406
donor. Allo-HCT is potentially effective by virtue of a graft-versus-myeloma (GvM) 
effect but currently, there is little available data regarding this treatment [22]. Given 
the action of daratumumab on the microenvironment, it could be used both to 
control the graft-versus-host disease and to improve the GvM effect. In the review 
by Nikolaenko et al., 34 patients treated with daratumumab after aploidentical HCT 
were evaluated [23]. The ORR after the treatment with the monoclonal antibody 
was 41%, only five cases of acute GVHD were reported and no cases of chronic 
GVHD, showing the efficacy of this strategy on a population of high-risk heavily 
pretreated patients. Based on this little data, we may speculate that the modification 
of microenvironment induced by daratumumab could be used to “plow the land” 
for the transplant. To our knowledge, none is known about the use of anti-CD38 as 
a bridge to the transplant. We recently reported the case of a young patients with 
relapsed myeloma after the standard induction therapy and a tandem ASCT who 
underwent 11 cycles of rescue therapy with daratumumab in combination with 
lenalidomide and dexamethasone, followed by haploidentical transplant. Thanks 
to this treatment, he achieved a partial response and is now on consolidation with 
Daratumumab-Rd regimen [24].
4. Daratumumab in untreated newly diagnosed multiple myeloma
More recently, the use of daratumumab has been also explored in the setting 
of newly diagnosed multiple myeloma (NDMM) patients, showing encouraging 
results both in the population of transplant eligible patients and in that of trans-
plant ineligible patients. The first results about daratumumab in NDMM patients 
proceed from a phase 1b study evaluating tolerability and safety of this monoclonal 
antibody in combination with myeloma backbone regimens: bortezomib-dexa-
methasone (VD), bortezomib-thalidomide-dexamethasone (VTD), bortezomib-
melphalan-dexamethasone (VMP), pomalidomide-dexamethasone (PD) [25]. 
NDMM patients were included in all the arms except the PD one: in the VD and 
VTD arms the patients were enrolled irrespective of the transplant eligibility, while 
all patients in the VMP arm were transplant ineligible. In all the four arms, daratu-
mumab was well tolerated and safe (Table 1b).
4.1  Daratumumab in untreated newly diagnosed multiple myeloma: transplant 
ineligible patients
ALCYONE and MAIA are the two main trials which evaluated the efficacy 
of adding daratumumab in the standard treatment of untreated patients with 
multiple myeloma ineligible to transplant. ALCYONE enrolled 706 naive patients 
randomized to receive VMP alone or with daratumumab [26]. Each cycle had a 
duration of 42 days. In the control group, all the patients received up to nine cycles 
of subcutaneous bortezomib, administered at the dosage of 1.3 mg per square 
meter of body-surface area (twice weekly on weeks 1, 2, 4, and 5 of cycle 1 and 
once weekly on weeks 1, 2, 4, and 5 of cycles 2 through 9), oral melphalan (9 mg 
per square meter, once daily on days 1 through 4 of each cycle), and oral predni-
sone (60 mg per square meter, once daily on days 1 through 4 of each cycle). In 
the experimental group, intravenous daratumumab at the usual dose of 16 mg/kg 
was administered with oral or intravenous dexamethasone at a dose of 20 mg once 
weekly in cycle 1, every 3 weeks in cycles 2 through 9, and every 4 weeks thereafter 
until disease progression or toxicity. Dexamethasone at a dose of 20 mg was sub-
stituted for prednisone on day 1 of each cycle. At 12 months, the PFS was 86.7% in 
the daratumumab group vs 76.0% in the control group. At the clinical data cut-off, 
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an event of disease progression or death had occurred in 88 (25.1%) patients in the 
daratumumab group vs 143 (40.2%) patients in the control group, with a hazard-
ratio of 0.50 in favour of the first group. The superiority was even confirmed in the 
older patients, in those with a poor performance status and worse stage. It seemed 
to be also independent from impairment of renal and liver function which were 
quite frequent in the enrolled population. In spite of this general advantage given 
adding daratumumab, a prespecified subgroup analysis of progression-free survival 
showed that the D-VMP combination is not so effective in the overcome of the 
bad prognosis given by the high-risk cytogenetics (defined by t (4;14), t (14;16), 
del17p). The main adverse effect was represented by infections of the respiratory 
tract but they were not a cause of discontinuation of treatment. MAIA compared 
Rd. to daratumumab-Rd [27]. The trial enrolled 737 naïve patients: in cycles of 
28 days, all of them received oral lenalidomide 25 mg on days 1 through 21 and 
oral dexamethasone 40 mg per week, until disease progression or toxicity. In the 
experimental group, daratumumab was added at a dose of 16 mg/kg once weekly 
during cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks 
thereafter. At the median follow-up of 28 months, PFS was not reached in the dara-
tumumab group and was 31.9 months in the control group. Disease progression or 
death occurred in 97 patients in the experimental group vs 143 in the control group, 
with a hazard-ratio of 0.56. Also in this trial, the benefit was maintained in older 
patients with worse performance status but not in the patients with high-risk cyto-
genetics. Pneumonia was recorded as the most frequent side effect in the experi-
mental group but it did not influence the general outcome. Based on the exciting 
results of ALCYONE and MAIA, several ongoing trials throughout the world aim to 
evaluate the benefit of adding both subcutaneous and intravenous daratumumab to 
the different combinations of drugs used for the induction of multiple myeloma in 
naïve unfit patients (NCT03993912, NCT03742297, NCT03652064, NCT03217812, 
NCT04052880, NCT04009109, NCT03695744, NCT02918331). Some of these 
are designed to study possibility of combining the monoclonal antibody with the 
newest generations of IMiDs and IPs: NCT4009109 is a phase II trial with two 
arms based on induction with lenalidomide, ixazomib, daratumumab and dexa-
methasone; maintenance in arm 1 is with the only lenalidomide, in the arm 2 it is 
with lenalidomide, ixazomib and daratumumab. Ixazomib is a last-generation IPs 
which recently received the approval to be used in combination with lenalidomide 
and steroid in RRMM. The interim analysis of this phase II trial showed an overall 
response rate (ORR) of 70%, with good molecular response [28].
4.2  Daratumumab in untreated newly diagnosed multiple myeloma: transplant 
eligible patients
The excellent results achieved in the population of unfit NDMM patients led to 
evaluate the efficacy of daratumumab also in the population of NDMM transplant 
eligible patients. CASSIOPEIA trial is the first largest study going in this direction: 
it enrolled 1085 patients across Europe, randomly assigned to the control arm with 
the use of VTD triplet or to the experimental arm adding daratumumab [29]. All 
patients received up to four 28-day, pre-transplant induction cycles and two 28-day, 
post-transplant consolidation cycles of subcutaneous bortezomib (administered 
according to the usual schedule), oral thalidomide (100 mg daily in all cycles), and 
oral or intravenous dexamethasone. Daratumumab was administered intravenously 
at a dose of 16 mg/kg of bodyweight once weekly in induction cycles 1 and 2 and 
once every 2 weeks during induction cycles 3 and 4 and consolidation. At 100 days 
post-transplant, the rate of sCR was higher in the daratumumab group than in the 
control group (29% vs 20%) and this superiority was maintained in older patients, 
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but not in patients with a higher stage disease and a higher risk cytogenetics. Also 
in this trial the main adverse events were represented by infections but none of 
them represented a cause of treatment discontinuation. Surprisingly, daratumumab 
went out to be associated with a reduction of the amount of collected stem cells 
CD34+ and the subsequent use of plerixafor, even if this aspect did not translate 
into a worse performance of the transplant. Recently, Voorhees et al. published the 
results of another study evaluating the use of daratumumab as first line in trans-
plant eligible patients, the GRIFFIN trial [30]. In this phase II randomized trial, 207 
enrolled patients received four 21-day induction cycles and two 21-day consolida-
tion cycles of oral lenalidomide (25 mg daily on days 1–14), subcutaneous bortezo-
mib (1.3 mg/m2 on days 1, 4, 8, and 11), and oral dexamethasone (VRD), followed 
by maintenance with lenalidomide until toxicity or progression disease. Patients 
in the experimental group received daratumumab (16 mg/kg) on days 1, 8, and 15 
of cycles 1 through 4 and day 1 of consolidation cycles and of maintenance cycles. 
After the end of post-transplant consolidation, the primary end-point of sCR was 
achieved in 42 patients in the experimental group vs 31 patients in the control group. 
Also the secondary end-points of overall response rate and rate of VGPR or better 
resulted higher in the daratumumab group. These good results deepened over time. 
The observed benefit was maintained also in the older population but not again 
in patients with a higher disease stage and with high-risk cytogenetics. As usually 
observed, also in this trial the experimental arm recorded a high rate of not statisti-
cally significant infections. Several ongoing trials aim to evaluate the use of daratu-
mumab as first-line in transplant eligible NDMM patients: among these, PERSEUS 
is a promising ongoing phase III trial evaluating efficacy of daratumumab plus VRD 
vs VRD in terms of PFS, utilizing subcutaneous daratumumab to minimize toxicity. 
There are also few ongoing trials evaluating induction with daratumumab irrespec-
tive of transplant eligibility and some of them are based on MRD-driven therapies 
(MASTER trial). The results of all these studies are awaited.
5. Daratumumab in other plasma cell neoplasms
Given the promising results in the treatment of multiple myeloma with dara-
tumumab, its use is being investigating also in the treatment of other plasma cell 
neoplasms, especially immunoglobulin light chain (AL) amyloidosis and smoulder-
ing myeloma (SMM).
5.1 Daratumumab in amyloidosis
AL amyloidosis is due to the production of misfolded immunoglobulin light chain 
by an aberrant plasma-cells clone. This pathologic protein deposits in a variety of 
organs, usually heart and kidney, causing serious dysfunction. In spite of good results 
showed by treatment of this disease with PIs and IMiDs [31, 32], there is still a signifi-
cant proportion of patients that do not respond to these agents. Based on a variety of 
reports showing safety and efficacy of daratumumab in patients with relapsed/refrac-
tory AL amyloidosis [33–36], some perspective trials have been recently conducted. 
NCT028441033 is a phase II study led at Boston Medical Center and aimed to evaluate 
safety and tolerability of daratumumab in a cohort of 25 participants with relapsed/
refractory AL amyloidosis. The preliminary results were encouraging, with only infu-
sion reactions being reported as main side effect [37]. The ORR is instead the primary 
outcome of a multi-center phase II study across France and Italy (NCT02816476): it 
enrolled 35 patients with AL amyloidosis not in VGPR or better after previous treat-
ment. The preliminary results showed an ORR of 59% with 44% of patients achieving 
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at least a VGPR [38]. These good results are confirmed by a report with the collabora-
tion of our group [39]: 59 patients out of 72 with relapsed/refractory AL amyloidosis 
achieved a hematologic response after eight infusions of daratumumab, single agent 
or combined with bortezomib and lenalidomide, and the quality of this response 
improved with the continuation of therapy. The demonstration of the efficacy of 
daratumumab in the treatment of AL amyloidosis provided the rationale for explor-
ing its use earlier in the disease course. Hossein Taghizadeh MA et al. presented the 
case of two patients with advanced cardiac involvement who achieved a normaliza-
tion of light chain levels within one cycle of therapy with the anti-CD38, without 
any serious adverse events in spite of the cardiac dysfunction [40]. A phase III trial 
comparing cyclophosphamide, bortezomib and dexamethasone with or without 
daratumumab in the first-line treatment of AL amyloidosis has recently completed 
the enrolment and the results are awaited (NCT03201965).
5.2 Daratumumab in SMM
Smouldering myeloma is defined by a medullar infiltration of clonal plasma-
cells ≥10% in the absence of symptoms. According to the Mayo Clinic criteria, 
M-protein >2 g/dl, medullar infiltration ≥20% and free-light chain ratio > 20 define 
risk categories. Patients with one, two and three of these criteria are considered to 
be at low, intermediate and high risk with 5-year progression of 23% in the low risk, 
47% in the intermediate risk and 82% in the high risk [41]. However, in spite of the 
important risk of transformation into symptomatic disease, current guidelines rec-
ommend “watch and wait” even in people with high and intermediate risk smoul-
dering myeloma. Since the earlier intervention may delay progression, different 
studies are evaluating the use of new drugs in this subset of patients. Daratumumab 
could be the perfect drug, given the efficacy and the tolerability showed in other 
subsets. Based on the good results of the CENTAURUS trial, a phase II study for 
patients with intermediate and high risk smouldering multiple myeloma, randomly 
assigned, in a 1:1:1 ratio, to receive one of three different schedules of daratumumab 
[42], a phase III trial has been designed (NCT03301220). In this study, patients with 
high-risk smouldering myeloma are randomized either to receive subcutaneous 
daratumumab or to be just monitored. Daratumumab is administered according to 
the usual schedule, until 39 cycles or up to 36 months or until confirmed disease 
progression or unacceptable toxicity. This study recently completed the enrolment 
and the results are still awaited but all the most recent findings suggest that the 
anti-CD38 could be used with safety and efficacy also in smouldering myeloma.
6. The dark side of daratumumab: adverse events
All pivotal studies leading to approval of daratumumab for the treatment of 
relapsed-refractory or newly diagnosed multiple myeloma showed a slight major 
susceptibility to infections in the studied populations. This risk seems to be due 
to the neutropenia and to the impairment of cellular immunity which is a direct 
consequence of targeting CD38 [43]. In the study by Nahi et al., nine patients out 
of 23 treated with daratumumab had viral and/or bacterial complications, mainly 
involving the respiratory tract. In these patients, assessment of circulating lym-
phocytes indicated a selective depletion of NK cells and viral reactivation after 
Daratumumab treatment. This finding is in line with data emerging from all the 
trials using anti-CD38-based regimens and suggest the necessity of screening for 
cytomegalovirus, Epstein–Barr virus and viral hepatitis before starting the treat-
ment, therefore an adequate antiviral and antibacterial prophylaxis in the treated 
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population. In the consensus document by ESCMID Study Group for Infections 
in Compromised Hosts (ESGICH), based on the pooled analysis of the two tri-
als GEN501 an SIRIUS, daratumumab is associated also with an increased risk of 
varicella-zoster virus (VZV) infections, especially in the presence of combination 
therapy with protease inhibitors and/or corticosteroids [44]. Anti-herpesvirus pro-
phylaxis with (val)acyclovir should be administered to VZV-seropositive patients 
at least 1 week before starting daratumumab therapy and for at least 12 weeks after 
its discontinuation. The consensus document also recommends seasonal-influenza 
vaccination. In the review of the drug conducted under the EMA’s accelerated 
assessment program for drugs that are of major interest for public health, also 
thrombocytopenia and anemia are reported as the most common side effects, 
besides neutropenia [45]. In this same report, half of all patients experienced infu-
sion-related reactions, mainly occurring at the first infusion. These reactions usu-
ally presented with nasal congestion, cough, throat irritation, chills, vomiting and 
nausea. Serious adverse reactions with bronchospasm, dyspnea, laryngeal edema, 
pulmonary edema and hypoxia have been also reported but in a few cases. Based on 
this phenomenon, EMA gave indication to premedicate every infusion with antihis-
tamines, antipyretics and corticosteroids. Furthermore, oral corticorsteroids should 
be taken by all patients on the first and second day after all infusions. Patients on 
therapy with Daratumumab may present with positive indirect and direct Coombs 
test, due to the CD38 expression also on the red blood cells. This interference could 
complicate the safe provision of blood products to people on treatment with this 
drug. Chapuy et al. demonstrated that this “laboratory side effect” might be solved 
by incubating red blood cells with dithiothreitol (DTT) or trypsin [46]. These 
reagents remove the CD38 on the surface of red blood cells, easing routine compat-
ibility testing. Evaluation of disease response in patients with multiple myeloma on 
treatment with daratumumab could also be complicated by this antibody. Given its 
proteic nature (IgG1), the drug can be confused with the endogenous monoclonal 
component during the interpretation of serum immunofixation electrophoresis 
(IFE). McCudden et al. proposed a daratumumab-specific immunofixation elec-
trophoresis reflex assay (DIRA) using a mouse anti-daratumumab antibody in 
order to discriminate between endogenous myeloma protein and daratumumab 
[47]. Both Castor and Pollux trials showed a slight increase of rates of secondary 
primary cancers in the experimental arms, within 6 months after the initiation of 
trials [16, 18]. Most of the cases were non-melanocytes related cutaneous tumours 
and occurred in patients already treated with IMiDs and alkylating agents. Further 
studies and longer follow-up are needed to clarify the potential carcinogenicity of 
Daratumumab. Another concern, regarding the use of daratumumab, is due to the 
expression of CD38 on the surface of CD34+ hematopoietic progenitor cells. This 
could theoretically translate into a delay in stem cells collection for eligible patients 
to ASCT on treatment with the monoclonal antibody. Xun Ma et al. conducted an 
assay in which specimens of mobilized peripheral blood CD34 + cells from myeloma 
patients were evaluated to determine percentage of CD38 expression and later 
incubated with daratumumab and complement-rich human serum. First, CD38 
is minimally expressed on CD34+ cells, compared to the control cell lines used. 
Furthermore, CDC did not occur, showing that, in vitro, daratumumab is not toxic 
to mobilized CD34 + progenitor cells from myeloma patients [48].
7. Conclusions
Daratumumab has showed proven efficacy and tolerability both in patients with 
RRMM and with NDMM, as confirmed in all the studies conducted during the last 
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years. A deep and durable response with easy-to-control side effects was obtained 
using this monoclonal antibody. The revolutionary power of this new drug could be 
also extended to patients with other plasma cell neoplasms, such as AL amyloidosis 
and SMM. Given the specific mechanisms of action of daratumumab targeting 
both clonal plasma-cells and bone-niche microenvironment, further studies are 
warranted to better understand the correct timing to introduce this monoclonal 
antibody in the context of a sequential therapy. On a side, the immune-mediated 
plasma-cell killing, induced by daratumumab in the early phase of treatment, acts 
as a debulking for the disease; on the other side, the restoration of the immune 
system may boost other metabolic effects of the monoclonal antibody, in a later 
phase of therapy, when the control of the disease is better [49]. Based on these 
hypothesis, the retreatment with daratumumab after a wash-out period may seem 
reasonable. Therefore, the anti-CD38 is a revolutionary weapon: understanding the 
best moment to use it in the battle against multiple myeloma is the great challenge 
of the future.
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